ABEC worked closely with the Novartis team to engineer the bioreactors to meet unique process, facility, and operational requirements. An integrated, modular design was developed and fully-tested at ABEC prior to shipment in order to minimize site installation and commissioning time. ABEC also advised on bioreactor scale-up to insure consistent performance with Novartis’ proven cell culture flu vaccine process in Marburg, Germany.
ABEC CEO Scott Pickering commented, “Novartis’ USFCC Project is a significant part of the national strategy for flu preparedness, and ABEC is proud to have participated. We delivered the bioreactors on time and on budget, and to the high levels of quality we are known for. Crucial to this success are ABEC’s experience and turn-key capabilities, which are a direct result of our long-term industry focus and continual investment in our company.”
About ABEC
For over 30 years, ABEC, Inc. has been a leader in delivering integrated process equipment solutions for biopharmaceutical manufacturing. ABEC is unique in its ability to engineer and manufacture the entire bioprocess, including bioreactors and fermentors, sanitary vessels, filtration and chromatography systems, and utility systems. ABEC is committed to the long-term health of our industry, our customers, and our employees. For more information, please visit www.abec.com.
